Encouraging results have been obtained on growth velocity in a number of cases, however patients with TRPS may present a remarkable impairment of bone status with a reduced bone mass and quality, making them unresponsive to the GH therapy [6, 16–20]. This evidence concerns the gene GH1 and trichorhinophalangeal syndrome.